Demin A A, Aksenova E A
Klin Med (Mosk). 2005;83(9):53-6.
The aim of the study was to evaluate efficiency of isosorbide-5-mononitrate (IMN) retard (40 to 80 mg/day) in 33 patients older than 60 with stable angina pectoris (functional class III-IV). The study shows that IMN is an effective and safe antianginal agent in treatment of patients with stable angina: it decreased the frequency of anginal attacks (from 4.1 +/- 0.34 to 0.8 +/- 0.13 per day, p < 0.0001), and additional nitroglycerin intake (from 2.2 +/- 0.32 to 0.2 +/- 0.05 tablets per day, p < 0.0001); according to the results of 24-hour ECG monitoring, it reduced ST-segment depression (from 2.2 +/- 0.17 to 0.9 +/- 0.09, p < 0.0001), preventing episodes of painful and silent myocardial ischemia (from 3.5 +/- 0.37 to 2.1 +/- 0.31, p < 0.0001); increased life quality as demonstrated by evaluation of physical (from 19.7 +/- 2.2 to 45.7 +/- 2.22, p < 0.0001), and mental (from 30.9 +/- 2.67 to 57.5 +/- 2.67, p < 0.0001) components using MOS-SF 36 questionnaire. Adverse effects of the drug (headache and hypotension) were observed in 6 (16.6%) patients.
本研究旨在评估单硝酸异山梨酯缓释片（IMN，40至80毫克/天）对33例60岁以上稳定型心绞痛（功能分级为III-IV级）患者的疗效。研究表明，IMN是治疗稳定型心绞痛患者的一种有效且安全的抗心绞痛药物：它降低了心绞痛发作频率（从每天4.1±0.34次降至0.8±0.13次，p<0.0001），以及硝酸甘油的额外摄入量（从每天2.2±0.32片降至0.2±0.05片，p<0.0001）；根据24小时心电图监测结果，它减少了ST段压低（从2.2±0.17降至0.9±0.09，p<0.0001），预防了疼痛性和无症状性心肌缺血发作（从3.5±0.37降至2.1±0.31，p<0.0001）；通过使用MOS-SF 36问卷评估身体（从19.7±2.2提高到45.7±2.22，p<0.0001）和精神（从30.9±2.67提高到57.5±2.67，p<0.0001）成分，提高了生活质量。6例（16.6%）患者观察到该药物的不良反应（头痛和低血压）。
